Are Biosimilars good to replace Remicade/Humira?

[Harshad]

Recently a biosimilar of Adalimumab called Exemptia was launched by Zydus Cadila Research Center. Company says it is a finger print match of Adalimumab. It was approved for Crohn's this April by the Drug Controller of India and scheduled to launch in Europe and US by 2020. Heard it's cheaper than Humira and Remicade.

Has anyone used a biosimilar of such a kind before, any experiences?

 

[DJW]

Has it been studied in the US and Europe?

I haven't heard of it so no help from me. Sorry.

 

[DJW]

Would it be the generic of infliximab? Is the patton coming to an end?

 

[my little penguin]

For example, Health Canada approved Inflectra for rheumatoid arthritis and psoriasis, but not for Crohn’s disease and ulcerative colitis, which Remicade is approved for, due to concerns that the differences between the two drugs could affect the SEB’s effectiveness and safety for those two conditions.

From

http://healthydebate.ca/2015/01/topic/seb-biosimilar-biologics

 

[Harshad]

Would it be the generic of infliximab? Is the patton coming to an end?

It is kinda like copy of Humira not infliximab. As you must be knowing Infliximab is made from human and rat protein unlike humira which is made from only human protein.
I went to see my Gastro doc and asked him to explain me about biosimilars, per him biosimilars are like carbon copy of the original drug. It's usually comes in handy for those who can't afford costly medicines. But the effectiveness and safety concerns are always there. He has asked not to go for it coz there are no records available as of now for it, so we do not want to take the risk.

I went to the company's website, per it, they have sent their drug to the labs in Europe and US but will take time of around 3 to 5 years for them to give any conclusion on it.